ArticleFrontiers in endocrinology2026
Characteristics of androgen metabolic pathways in patients with 21-hydroxylase deficiency and their association with disease control status.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the activity characteristics of distinct androgen metabolic pathways in patients with 21-hydroxylase deficiency (21OHD) and their correlation with disease control status, and to elucidate the metabolic pathway features and underlying mechanisms in poorly controlled patients. Methods: A total of 111 patients with confirmed 21OHD were enrolled in this study. Clinical data and steroid hormone profiles were collected, and robust standardized Z-scores were calculated for each steroid hormone. K-means clustering analysis was performed using the robust standardized Z-scores of 7 signature steroid hormones to stratify patients into a well-controlled group and a poorly controlled group. Differences in clinical characteristics, pathway activities and key enzyme conversion efficiencies were compared between and within the two groups. Results: K-means clustering analysis classified 102 patients into the well-controlled group and 9 into the poorly controlled group. Multivariate analysis identified puberty as an independent risk factor for poor disease control (OR = 11.90, 95%CI:1.43-98.79, P = 0.02). Among pubertal patients, the poorly controlled group had a significantly higher relative weight of classical pathway androgen load than the well-controlled group (63.92% vs. 46.19%, P = 0.02), and the proportion of the classical pathway in the poorly controlled group was markedly higher than that of the 11-oxygenated and backdoor pathways (both P<0.05). Additionally, the conversion efficiency of the 21-deoxycortisol (21DOF) pathway was significantly decreased in the poorly controlled group (P = 0.004), suggesting relatively restricted CYP11B1 activity which drives the shift of androgen metabolism toward the classical pathway. Conclusion: In poorly controlled pubertal patients with 21OHD, the relative insufficiency of CYP11B1 activity and the dysregulation of the metabolic network jointly lead to the shift of androgen synthesis to the classical pathway, forming a "classical pathway dominance". This finding deepens the understanding of the pathological mechanism of 21OHD from the perspective of pathway dynamics and provides a novel theoretical basis for individualized clinical treatment of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.